Trials / Completed
CompletedNCT04721223
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
A Phase 1b/2a, Multi-Center, Open-Label，Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JAB-3068 in Combination With JS001 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of JAB-3068 administered in investigational regimens in adult participants with advanced solid tumors.
Detailed description
To assess the safety and tolerability and determine the recommended phase 2 dose (RP2D) of JAB-3068 in combination with PD1 inhibitor in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
- Esophageal Squamous Cell Carcinoma
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JAB-3068 | JAB-3068 administrated orally as a tablet. |
| DRUG | PD1 inhibitor | JS001 administrated as an intravenous(IV) infusion. |
Timeline
- Start date
- 2021-04-26
- Primary completion
- 2023-12-29
- Completion
- 2023-12-29
- First posted
- 2021-01-22
- Last updated
- 2024-09-19
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04721223. Inclusion in this directory is not an endorsement.